Vir Biotechnology CEO Says Its COVID-19 Treatment “Stands Up Well” To All Virus Variants
November 18, 2021
CNBC (11/17, Towey) reports “a monoclonal antibody Covid treatment from Vir Biotechnology and GlaxoSmithKline ‘stands up well’ to all variants of the virus, Vir President and CEO George Scangos” said Wednesday. The comments “came after the two companies a...